Pharming Group NV
AEX:PHARM
Pharming Group NV
Stock-Based Compensation
Pharming Group NV
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Stock-Based Compensation
$11.9m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Stock-Based Compensation
€3.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
11%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
argenx SE
XBRU:ARGX
|
Stock-Based Compensation
$243.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Stock-Based Compensation
$72m
|
CAGR 3-Years
46%
|
CAGR 5-Years
52%
|
CAGR 10-Years
65%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Stock-Based Compensation
$3.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
76%
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Stock-Based Compensation?
Stock-Based Compensation
11.9m
USD
Based on the financial report for Sep 30, 2025, Pharming Group NV's Stock-Based Compensation amounts to 11.9m USD.
What is Pharming Group NV's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
38%
Over the last year, the Stock-Based Compensation growth was 0%. The average annual Stock-Based Compensation growth rates for Pharming Group NV have been 38% over the past three years .
